F S&P 500
5,313.50 +9.50 (+0.18%) F Dow Jones
38,869.00 +82.00 (+0.21%) F Nasdaq
18,758.25 +57.25 (+0.31%) E-mini Russell 2000 Index Futur
2,044.40 +6.90 (+0.34%) Petróleo
73.20 -0.05 (-0.07%) Oro
2,356.70 +9.30 (+0.40%)
Hofseth BioCare ASA (HBQ.F)
Hofseth BioCare ASA
Keiser Wilhelms gate 24
Ålesund 6003
Norway
47 73 10 22 00
https://www.hofsethbiocare.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 69
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Jon Olav Odegard | Chief Executive Officer | 249.23k | N/D | N/D |
| Ms. Christel Elise Kanli | CFO & COO | 126.94k | N/D | N/D |
| Dr. Bomi Framroze | Chief Scientific Officer | 828.04k | N/D | 1961 |
| Mr. James Berger | Chief Commercial Officer | 43.95k | N/D | N/D |
| Ms. Angelika Florvaag | Chief Quality Officer | 110.53k | N/D | N/D |
Descripción
Hofseth BioCare ASA operates as a consumer and pet health ingredient supplier and incubator in Norway, the United Kingdom, France, Belgium, Europe, Japan, Asia, and the United States. The company's products include OmeGo, a salmon oil, which offers the full spectrum of fatty acids and omegas found naturally in fresh whole salmon; ProGo, a bioactive peptide for VMS, metabolism, and active nutrition needs; CalGo, an absorbable complex mineral for bone and joint health; CollaGo; and PetGo, a non-soluble protein. The company was incorporated in 2000 and is headquartered in Ålesund, Norway.
Gestión corporativa
La calificación ISS Governance QuickScore de Hofseth BioCare ASA a partir del 1 de junio de 2024 es 10. Las puntuaciones principales son Auditoría: 10; Junta: 9; Derechos del accionista: 10; Compensación: 10.
